1-11 of 11
Stephen P. Anthony
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168

Britten Gordon, Elizabeth Muhowski, Janani Ravikrishnan, Samon Benrashid, Andrew Mitchell, Alexander He, Shrilekha Misra, Tzung-Huei Lai, Shanmugapriya Thangavadivel, Alexander Marr, Lianbo Yu, Brandi Walker, Elizabeth Perry, Kerry A Rogers, Adam S Kittai, Seema A Bhat, John C. Byrd, Deepa Sampath, Rosa Lapalombella, Weiguo Han, Neil E. Kay, Yi Chen, Fenlai Tan, Stephen P. Anthony, Yu Chen, Jennifer A. Woyach
Journal: Blood
Blood (2023) 142 (Supplement 1): 416.
https://doi.org/10.1182/blood-2023-178259
Published: 2023
Journal Articles

Pre-Clinical Evaluation of a New-Generation Orally Bioavailable Dual Bcl-2/Bcl-Xl Inhibitor LP-118 in Mantle Cell Lymphoma

Ling-Ling Lee, Cong Zhu, Brianna Feldmeier, Yao Chen, Wenyu Li, Yu Chen, Stephen P. Anthony, Yue Shen, Fenlai Tan, Yi Chen, Bing Dai
Journal: Blood
Blood (2023) 142 (Supplement 1): 3640.
https://doi.org/10.1182/blood-2023-180190
Published: 2023
Journal Articles

Initial Results of a Phase 1 Dose Escalation Study of LP-168, a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase

Jennifer A. Woyach, Deborah M. Stephens, Danielle M Brander, Adam S Kittai, Boyu Hu, Andrea Sitlinger, Emily K Curran, Fenlai Tan, Yi Chen, Stephen P. Anthony, Yu Chen, John C. Byrd
Journal: Blood
Blood (2023) 142 (Supplement 1): 328.
https://doi.org/10.1182/blood-2023-186432
Published: 2023
Journal Articles

LP-118, a Novel BCL2 Inhibitor, Shows Potent in Vitro Anti-Myeloma Activity

Rodrigo Fonseca, Yuan Xiao Zhu, P. Leif Bergsagel, Marta Chesi, Akhilesh Pandey, Kiran Mangalaparthi, Yi Chen, Felai Tan, Stephen P. Anthony, Yu Chen, Yue Shen, Bing Dai, Esteban Braggio, Rafael Fonseca
Journal: Blood
Blood (2022) 140 (Supplement 1): 7129–7130.
https://doi.org/10.1182/blood-2022-167372
Published: 2022
Journal Articles

LP-118, a Selective Bcl-2 Inhibitor with Tuned Bcl-Xl Activity, Causes Myeloid Differentiation and Cell Death in Acute Myeloid Leukemia (AML)

Kristin L Koenig, Colin Brame, Steven Sher, Larry Beaver, Casey B. Cempre, Katie Williams, Matthew Purcell, Bonnie Harrington, Yi Chen, Felai Tan, Stephen P. Anthony, Yu Chen, Yue Shen, John C. Byrd, Rosa Lapalombella
Journal: Blood
Blood (2022) 140 (Supplement 1): 9068–9069.
https://doi.org/10.1182/blood-2022-170578
Published: 2022
Journal Articles

Targeting Apoptosis with Novel BH3 Mimetics in T-Lineage Acute Lymphoblastic Leukemia

Caner Saygin, Bartholomew Eisfelder, Giorgia Giordano, Anika Thomas-Toth, Yi Chen, Felai Tan, Stephen P. Anthony, Yu Chen, Yue Shen, James LaBelle, Wendy Stock
Journal: Blood
Blood (2022) 140 (Supplement 1): 10689–10690.
https://doi.org/10.1182/blood-2022-163673
Published: 2022
Journal Articles

Characterization of LP-118, a Novel Small Molecule Inhibitor of Bcl-2 and Bcl-Xl in Chronic Lymphocytic Leukemia Resistant to Venetoclax

Janani Ravikrishnan, Elizabeth M. Muhowski, Tzung-Huei Lai, Shrilekha Misra, Daisy Diaz Rohena, Felai Tan, Yi Chen, Stephen P. Anthony, Yu Chen, Yue Shen, John C. Byrd, Deepa Sampath, Jennifer A. Woyach
Journal: Blood
Blood (2021) 138 (Supplement 1): 679.
https://doi.org/10.1182/blood-2021-151852
Published: 2021
Journal Articles

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Acute Myeloid Leukemia (AML): Results of Newly Diagnosed High-Risk Exploratory Arm

Joshua F. Zeidner, MD, Daniel J. Lee, MD, Gil Fine, PhD, Eunice S. Wang, MD, Vijaya R. Bhatt, MD, Andrew Dalovisio, MD, Pau Montesinos, MD PhD, Kathryn S. Kolibaba, MD, Stephen P. Anthony, DO, David J. Bearss, PhD, B. Douglas Smith, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 48–50.
https://doi.org/10.1182/blood-2020-133796
Published: 2020
Journal Articles

A Phase 1 Study of TP-3654, an Orally-Delivered PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

Claudia Lebedinsky, MD, Stephen P. Anthony, DO, Golam Mohi, PhD, Huyuan Yang, PhD, Jian Mei, PharmD, Edgar Braendle, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-134039
Published: 2020
Journal Articles

Phase 1, Open-Label, Randomized, Bioequivalence Study of 2 Bendamustine Hydrochloride Formulations; A Ready-to-Dilute Low-Volume, Rapid Infusion Solution and a Lyophilized Powder Formulation

W Jeffrey Edenfield, MD, Bassam Mattar, MD, Stephen P Anthony, DO, Peter Mutch, Brian Chanas, Mark Smith
Journal: Blood
Blood (2015) 126 (23): 4857.
https://doi.org/10.1182/blood.V126.23.4857.4857
Published: 2015
Journal Articles

Comparative Safety of Two Bendamustine Hydrochloride Formulations; A Ready-to-Dilute Low-Volume, Rapid Infusion Solution, and a Lyophilized Powder: Results from a Phase 1 Study

Bassam Mattar, MD, Stephen P Anthony, DO, W Jeffrey Edenfield, MD, Mark Smith, Adrian Hepner
Journal: Blood
Blood (2015) 126 (23): 4861.
https://doi.org/10.1182/blood.V126.23.4861.4861
Published: 2015